Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024
Fractyl Health (Nasdaq: GUTS) has announced upcoming presentations of weight maintenance data from its Revita and Rejuva platforms at ObesityWeek 2024, scheduled for November 2-6 in San Antonio, Texas. The company will showcase two key presentations:
1. An oral presentation on islet-targeted GLP-1 receptor agonist gene therapy's effects on fat reduction and metabolism improvement in obese mice, scheduled for November 5.
2. A poster presentation demonstrating how duodenal mucosal resurfacing maintains weight loss in metabolic disease, to be presented during the Welcome Reception on November 3.
These presentations highlight Fractyl Health's commitment to developing innovative treatments for obesity and Type 2 Diabetes by addressing their root causes.
Fractyl Health (Nasdaq: GUTS) ha annunciato le prossime presentazioni dei dati sulla gestione del peso delle sue piattaforme Revita e Rejuva durante ObesityWeek 2024, in programma dal 2 al 6 novembre a San Antonio, Texas. L'azienda presenterà due interventi chiave:
1. Una presentazione orale sugli effetti della terapia genica con agonisti del recettore GLP-1 mirati alle isole sulla riduzione del grasso e sul miglioramento del metabolismo in topi obesi, in programma per il 5 novembre.
2. Una presentazione poster che dimostra come il ripristino della mucosa duodenale mantenga la perdita di peso nelle malattie metaboliche, che sarà presentata durante la Reception di Benvenuto il 3 novembre.
Queste presentazioni evidenziano l'impegno di Fractyl Health nello sviluppo di trattamenti innovativi per l'obesità e il diabete di tipo 2, affrontando le loro cause profonde.
Fractyl Health (Nasdaq: GUTS) ha anunciado presentaciones próximas de datos sobre el mantenimiento del peso de sus plataformas Revita y Rejuva en ObesityWeek 2024, programado del 2 al 6 de noviembre en San Antonio, Texas. La compañía mostrará dos presentaciones clave:
1. Una presentación oral sobre los efectos de la terapia génica con agonistas del receptor GLP-1 dirigidos a islotes en la reducción de grasa y la mejora del metabolismo en ratones obesos, programada para el 5 de noviembre.
2. Una presentación en póster que demuestra cómo la resurfacing de la mucosa duodenal mantiene la pérdida de peso en enfermedades metabólicas, que se presentará durante la Recepción de Bienvenida el 3 de noviembre.
Estas presentaciones destacan el compromiso de Fractyl Health para desarrollar tratamientos innovadores para la obesidad y la Diabetes Tipo 2 abordando sus causas fundamentales.
Fractyl Health (Nasdaq: GUTS)는 Revita 및 Rejuva 플랫폼의 체중 유지 데이터를 ObesityWeek 2024에서 발표할 예정이라고 발표했습니다. 이 행사는 텍사스 주 샌안토니오에서 11월 2일부터 6일까지 열립니다. 회사는 두 가지 주요 발표를 준비했습니다:
1. 비만 생쥐에서 지방 감소와 신진대사 개선에 대한 이자극 GLP-1 수용체 작용제 유전자 치료의 효과에 관한 구두 발표가 11월 5일 예정되어 있습니다.
2. 대장 점막 resurfacing이 대사 질환에서 체중 감소를 지속하는 방법을 보여주는 포스터 발표가 11월 3일의 환영 리셉션 중에 진행됩니다.
이 발표들은 비만과 제2형 당뇨병의 근본 원인을 해결함으로써 혁신적인 치료법 개발에 대한 Fractyl Health의 헌신을 강조합니다.
Fractyl Health (Nasdaq: GUTS) a annoncé les prochaines présentations des données sur le maintien du poids de ses plateformes Revita et Rejuva lors de ObesityWeek 2024, prévu du 2 au 6 novembre à San Antonio, Texas. L'entreprise présentera deux interventions clés :
1. Une présentation orale sur les effets de la thérapie génique avec des agonistes du récepteur GLP-1 ciblant les îlots sur la réduction des graisses et l'amélioration du métabolisme chez des souris obèses, prévue pour le 5 novembre.
2. Une présentation d'affiche montrant comment le resurfaçage de la muqueuse duodénale maintient la perte de poids dans les maladies métaboliques, qui sera présentée lors de la Réception de Bienvenue le 3 novembre.
Ces présentations mettent en avant l'engagement de Fractyl Health à développer des traitements innovants pour l'obésité et le diabète de type 2, en s'attaquant à leurs causes profondes.
Fractyl Health (Nasdaq: GUTS) hat die bevorstehenden Präsentationen von Daten zur Gewichtserhaltung seiner Revita- und Rejuva-Plattformen bei ObesityWeek 2024 angekündigt, die vom 2. bis 6. November in San Antonio, Texas stattfinden wird. Das Unternehmen wird zwei wichtige Präsentationen zeigen:
1. Ein mündlicher Vortrag zu den Auswirkungen der gentransferierten GLP-1-Rezeptor-Agonisten-Therapie auf die Fettreduzierung und die Verbesserung des Stoffwechsels bei fettleibigen Mäusen, der für den 5. November geplant ist.
2. Eine Posterpräsentation, die zeigt, wie die duodenale Schleimhautverjüngung den Gewichtsverlust bei Stoffwechselerkrankungen aufrechterhält, die während des Willkommensempfangs am 3. November präsentiert wird.
Diese Präsentationen unterstreichen das Engagement von Fractyl Health, innovative Behandlungen für Fettleibigkeit und Typ-2-Diabetes zu entwickeln, indem die zugrundeliegenden Ursachen angegangen werden.
- None.
- None.
BURLINGTON, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced that it will present compelling weight maintenance data from both its Revita and Rejuva platforms at The Obesity Society’s Annual Meeting at ObesityWeek 2024, held from November 2-6, 2024, in San Antonio, Texas.
Oral Presentation
- Title: Islet-Targeted GLP-1 Receptor Agonist Gene Therapy Reduces Fat and Improves Metabolism in Obese Mice
- Presentation Date & Time: Tuesday, November 5, 2024, 10:45 am - 11:00 am (CDT)
- Location: Henry B. Gonzalez Convention Center, Room 007
Poster Presentation
- Title: Duodenal Mucosal Resurfacing Durably Maintains Weight Loss in Metabolic Disease
- Presentation Date & Time: Sunday, November 3, 2024, 7:30 pm – 8:30 pm (CDT)
- Location: Henry B. Gonzalez Convention Center Exhibit Hall, Welcome Reception
About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit www.fractyl.com or https://twitter.com/FractylHealth.
About Revita
Fractyl Health’s lead product candidate, Revita, is based on the company’s insights surrounding the potential role of the gut in obesity and T2D. Revita is designed to remodel the duodenal lining via hydrothermal ablation (i.e., duodenal mucosal resurfacing) to edit abnormal intestinal nutrient sensing and signaling mechanisms that are a root cause of metabolic disease. Revita has received a CE mark in Europe and, in January 2022, received reimbursement authorization through NUB in Germany for the treatment of T2D. In the United States, Revita is for investigational use only under US law. It has US FDA Breakthrough Device designation in weight maintenance for people with obesity who discontinue GLP-1 based drugs, as well as in insulin-treated T2D. A pivotal study of Revita in weight maintenance for patients with obesity after discontinuation of GLP-1-based drugs, called REMAIN-1, is underway with anticipated data readouts from the open-label study in weight maintenance in the fourth quarter of 2024 and an anticipated mid-point analysis of the REMAIN-1 in the second quarter of 2025. A pivotal study of Revita in patients with T2D who are inadequately controlled on any glucose lowering agent, REVITALIZE-1, is currently enrolling in the United States and Europe.
About Rejuva
Fractyl Health’s Rejuva platform focuses on developing next-generation adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform is in preclinical development and has not yet been evaluated by regulatory agencies for investigational or commercial use. Rejuva leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas. The program aims to transform the management of metabolic diseases by offering novel, disease-modifying therapies that address the underlying root causes of disease.
Contacts
Corporate Contact
Lisa Davidson, Chief Financial Officer
ir@fractyl.com, 781.902.8800
Media Contact
Jessica Cotrone, Corporate Communications
jcotrone@fractyl.com, 978.760.5622
Investor Contact
Stephen Jasper, Gilmartin Group
stephen@gilmartinir.com, 619.949.3681
FAQ
What will Fractyl Health (GUTS) present at ObesityWeek 2024?
When and where is Fractyl Health's (GUTS) presentation at ObesityWeek 2024?
What are the two treatment platforms Fractyl Health (GUTS) is presenting data on?
What conditions does Fractyl Health (GUTS) aim to treat with their platforms?
